Graphical abstract potential antineoplastic agents from chloro ethyl urea series E. Moreau et al. Bioorg. Med. Chem. 2005, 13, 6703-6712 2 Abstract: In our ongoing research program aimed at the optimization of microtubule-selfassembly disrupting agents, we have prepared three series of phenylurea analogues (CEU), derived from N-(3--hydroxyalkyl or 4--hydroxyalkyl or 3--hydroxyalkynyl)phenyl-N'-(2-chloroethyl)ureas. Most compounds exhibit potent growth inhibitory activity on human colon carcinoma HT-29, human skin melanoma M21, and human breast carcinoma MCF-7 tumor cell lines, with a GI50 ranging from 250 nM to 8 M. Among these new molecules, three CEUs exhibit GI50 in the nanomolar range. They are more potent by approximately an order of magnitude than previously described CEU analogues. As such, they are attractive hit compounds for the development of potent new alkylating antitubulin drugs. E. Moreau et al. Bioorg. Med. Chem. 2005, 13, 6703-6712 
Introduction
Cancers are a group of malignant diseases responsible for tremendous health costs associated with high level of mortality and morbidity. As a result, numerous chemotherapeutic agents have been developed to impede the progression of malignant tumors or prevent their recurrence. Chemotherapeutic treatments are largely palliative and are useful for limited periods of time. 1 Chemotherapeutic agents often fail when drug resistant tumor cells become predominant, when the dose-related toxicity is too high to obtain optimal anticancer activity or when side effects are simply unbearable. Amongst the anticancer agents developed in the past decades, molecules acting on the cellular microtubule dynamics form one of the largest group of effective chemotherapeutics.
Microtubules are heterodimers composed of -and -tubulin isoforms. Microtubules' assembly forms cytoskeleton components, present in all eukaryotic cells. 2 During mitosis, microtubules are highly dynamic and are constantly reshaping in fast polymerizationdepolymerisation processes. When natural or synthetic ligands interact with microtubule dynamics, they disrupt the cytoskeleton and block mitosis into the G2/M phase. Cells then initiate an apoptotic program. Tubulin cellular importance still makes it an attractive target for the development of potent anticancer drugs. 3 Antitubulin agents 4 bind to tubulin according to four different modes. 5 In the first mode, drugs bind preferentially to polymerized tubulin. It includes the well-known paclitaxel and other members, such as epothilone B, discodermolide, and dyctyostatin. 4, 5 For the three other modes, agents either form a covalent link to tubulin cysteine residues, bind to the colchicine site, or bind in the vinca domain. Vinblastine, vincristine, and peptides, such as dolastatins and hemiasterlins, are agents acting on the vinca domain. 4, 5 Colchicine, 6 combretastatin, 7 and podophyllotoxins 8 interact with the colchicine-binding site. The site is located on -tubulin at the interface between -and -tubulins, close to the T7 loop and the H8 helix. 9 Ligand interactions with the colchicinebinding site are mainly electrostatic in nature (docking) and thus reversible for most compounds. N-phenyl-N'-(2-chloroethyl)ureas (CEUs) 10 form a covalent link with cysteine residue within the colchicine-binding site. Originally developed by our laboratory, CEUs react specifically with a few proteins, including -tubulin. 10 We demonstrated that CEUs substituted at the 4-position of the phenyl ring by hydrophobic moieties are potent tumor cell growth inhibitors. They act as angiogenesis inhibitors both in vitro and in vivo. 11 They also inhibit tumor cell growth in vivo on the murine colon carcinoma CT-26 model. 12 Interestingly, some CEU derivatives have been shown to be orally bioavailable. 13 The antimicrotubule activity of many CEUs is based on the alkylation of an amino acid within the colchicine-binding site. We showed that CEU-022, that is, N-[4-(1,1-dimethylethyl)-phenyl-N'-(2-chloroethyl)urea, alkylates specifically the cysteine 239 residue of tubulin. 10 -Tubulin alkylation by CEUs can be detected in an electrophoretic shift assay. 14 In the context of pharmacomodulating the properties of N-phenyl-N'-(2-chloroethyl)ureas, we prepared molecules with phenyl ring substituents bearing terminal functional group that are more hydrophilic to alter the molecules biodistribution and toxicity in animal pharmacokinetics and metabolism studies. We describe here the synthesis and growth inhibition activity of three different series of derivatives designed as N-(3--hydroxyalkyl or 4--hydroxyalkyl or 3--hydroxyalkynyl)phenyl-N'-(2-chloroethyl)ureas. Therefore, commercially available 3-hydroxyaniline was converted into the corresponding N-(hydroxyphenyl)-N'-(2-chloroethyl)urea (1a). Compounds 1b and c were also obtained by direct addition of the respective anilines 2 and 3 to 2-chloroethylisocyanate in dry dichloromethane. Anilines 2 and 3 were obtained through the reduction of the nitro group of commercially available 3-nitrobenzylalcohol and 2-(3-nitrophenyl)-1-ethanol using metallic reduction with SnCl22H2O in ethanol. Scheme 2 describes the approach used to introduce longer hydroxyalkyl chains in compounds 1d-k. We undertook a Sonogashira-like 17,18 addition with propargyl alcohol, 3-butyn-1-ol, 4-pentyn-1-ol, 5-hexyn-1-ol 19 or 6-heptyn-1-ol, mixed with 1-iodo-3nitrobenzene (8), using Pd(0)/PPh3 as catalyst. The reactions proceeded smoothly to afford the corresponding -hydroxyalkynyl derivatives 4d-h 20 in yields ranging from 43% to 88%. Compounds 4d-h 20 were then converted into the corresponding anilino-hydroxyalkyl derivatives 5d-h 21 by hydrogenation in ethanol using palladium on carbon as catalyst. Compounds 5d-h 21 were obtained in yields ranging from 80% to 100%.
Results and discussion
Afterwards, the latter products were converted into their corresponding 2-chloroethylureas 1d-h by addition of 2-chloroethylisocyanate to anilines 5d-h 21 in dry dichloromethane with 28% to 51% urea yields. Compounds 6d-f were prepared by chemoselective reduction of the aromatic nitro group of compounds 4d-f by catalytic reduction using iron in a mixture of concentrated hydrochloric acid and ethanol to obtain 6d-f in fair to good yields. Finally, compounds 6df were converted into 1i to 1k by addition of 2-chloroethylisocyanate with 51% to 63% yields. 
Growth inhibition activity
The growth inhibition assays 22 were conducted twice in triplicate on three human tumor cell lines of different tissue origin. The tumor cell lines used were HT-29 (human colon carcinoma), M21 (human skin melanoma), and MCF-7 (human breast carcinoma), respectively. Growth inhibition activity is expressed in terms of GI50 value (M), which is the drug concentration required to inhibit tumor cell growth by 50%. Table 1 summarizes the ability of 1a-h to inhibit tumor cell growth. After two days of treatment, the GI50 value was determined using the NIH sulforhodamine assay.
Compounds 1a-c bearing short saturated -hydroxyalkyl side chains (n < 3) were inactive at the concentrations tested. Interestingly, compounds 1d-h bearing longer hydroxyalkyl side chains had a significant impact on growth inhibition activity in all tumor cells tested as the side chain increased, reaching the best GI50 value at five carbon atoms. The growth inhibition potency of compounds 1d-f inspired us to prepare compounds 1l-n, substituted in position 4 of the aromatic ring, instead of position 3 with identical hydroxyalkyl chains (see Table 2 ). There was no impact on growth inhibition activity by compounds 1l-n at the concentration tested, as opposed to compounds 1d-f. However, CEUs substituted by alkyl moieties in 4-position or an iodine atom (see Table 3 ) 23 demonstrated a much better growth inhibition activity. The switch from 4-to 3-position with hydroxyalkyl chains generated CEU compounds 1d-f with a growth inhibition activity improved by an order of magnitude compared to the previous CEUs with the best growth inhibition activity (see Table 3 ). Table 3 . Previously synthesized compounds with the best growth inhibition activity. 23 Compound Names GI50 (M)
The impact of substituents in position 3 was evaluated further by increasing the rigidity of the -hydroxyalkyl side chain with the introduction of a triple bond. It seems to abrogate the growth inhibition activity (see Table 4 ). 
We are contemplating two hypotheses to explain the increase in cell growth inhibition activity due to: (i) the three isomeric form, (ii) less rigid forms of potent CEU, and (iii) the effect of -hydroxyalkyl side chains in position 3 as opposed to position 4. The first hypothesis is based on a model of colchicine interactions that we are developing to its own -tubulin binding site where a hydrogen or -bond interaction could take place between an oxygen atom on the colchicine C ring and a key amino acid in tubulin. 24 In that context and based on previous alkylation results of -tubulin by a CEU moiety, 10 terminal hydroxyl group is the cause of an increase in potency and optimal combination.
Conclusion
In summary, compounds 1f-h appear to be essentially equivalent with GI50 in the nanomolar range if we consider structure-activity relationships. These three CEUs are approximately 1 order of magnitude more potent than all hydrophobic CEUs tested so far (see Table 3 ). These findings demonstrate that the growth inhibition activities of N-(3-- CEUs' computer modelization within the recently available cocrystallized colchicine-and -tubulin coordinates 9 will be used to test the stabilizing effect of 3--hydroxyalkyl substituents.
Experimental

Cell growth inhibition assay
The growth inhibition potency of CEUs was assessed using the procedure described by the National Cancer Institute for its drug screening program. 22 Liquid flash chromatography was performed on silica gel 60 A (American Chemicals Ltd., Montreal, Canada), using the indicated solvent mixture expressed as volume/volume ratios. Solvents and reagents were used without purification unless specified otherwise.
The progress of all reactions was monitored using TLC on precoated silica gel plates (Merck Silica Gel 60 F254). The chromatograms were viewed under UV light at 254 nm.
For column chromatography, Merck Silica Gel (70-230 mesh) was used. Hz, CH2), 3.07 (br s, 2H, NH2), 2.37 (t, 2H, J = 6.0 Hz, CH2), 1.63 (m, 4H, CH2); 13 
